Status:
TERMINATED
A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
Takeda Pharmaceuticals North America, Inc.
Conditions:
Obesity
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Following screening, eligible subjects will be enrolled into a 6-week Low Calorie Diet (LCD) lead-in period. Subjects who lose at least 2% of their body weight at the end of the 6-week LCD lead-in per...
Eligibility Criteria
Inclusion
- Is obese with a BMI ≥35 to ≤45 kg/m2.
- Has stable body weight (not varying by \>5% within 3 months prior to study start).
- Meets certain requirements with respect to concomitant medications.
- Has not smoked or used nicotine-containing products for at least 12 months prior to study start.
Exclusion
- Has not been enrolled in a weight loss program within 2 months prior to study start.
Key Trial Info
Start Date :
January 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
213 Patients enrolled
Trial Details
Trial ID
NCT01235741
Start Date
January 1 2011
End Date
September 1 2011
Last Update
April 15 2015
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Greenbrae, California, United States
2
Research Site
La Jolla, California, United States
3
Research Site
Denver, Colorado, United States
4
Research Site
Winter Park, Florida, United States